SCHEMBL6095057

SCHEMBL6095057

CCOC(=O)c1nc(N2CCNCC2)n(C)c(=O)c1OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.43
HTR6 P50406 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPK13 O15264 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK11 Q15759 1/20 0.40
MAPK14 Q16539 1/20 0.40
HTR2C P28335 2/20 0.40
HTR1A P08908 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
USP2 O75604 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6095402 0.89 ALDH1A1 (0.50) DPP4ADORA3KDM4EALDH1A1USP2
SCHEMBL6086680 0.89 ALDH1A1 (0.41) KDM4EALDH1A1LMNATSHRNPSR1
SCHEMBL5303358 0.88 ALDH1A1 (0.39) KDM4EALDH1A1LMNATSHRNPSR1
SCHEMBL6086561 0.87 TSHR (0.40) KDM4EHTR1AALDH1A1LMNATSHR
SCHEMBL6094216 0.87 EGFR (0.39) KDM4EALDH1A1LMNATSHRNPSR1
SCHEMBL6094824 0.86 DCTPP1 (0.41) KDM4EALDH1A1LMNATSHRNPSR1
SCHEMBL6087390 0.84 PTPN11 (0.39) KDM4EALDH1A1LMNATSHRNPSR1
SCHEMBL6086734 0.83 OPRM1 (0.42) ALDH1A1LMNATSHRNPSR1USP2
SCHEMBL6088848 0.82 PTPN11 (0.39) KDM4EALDH1A1LMNATSHRNPSR1
SCHEMBL3416727 0.81 KMT2A (0.46) KDM4EALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135467-B2 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY (US) 2006-11-14 US disclosed
US-20040204498-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-10-14 US disclosed
WO-2004062613-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204498-A1 HIV integrase inhibitors IMPDH1, TYMP, REV1 DPP4 2465/4885HTR6 3154/4885ADORA3 1923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.